Skip to main content

Advertisement

Fig. 3 | Alzheimer's Research & Therapy

Fig. 3

From: SAR228810: an antibody for protofibrillar amyloid β peptide designed to reduce the risk of amyloid-related imaging abnormalities (ARIA)

Fig. 3

Chronic treatment with SAR255952 prevents amyloid β (Aβ) peptide plaque deposition and brain microglial activation in APPSL transgenic Alzheimer’s mice. Animals were treated for 20 weeks once weekly by the intraperitoneal route with the indicated doses of antibodies starting from the age of 2 months. a Whole scanned Aβ-immunostained sagittal brain tissue section illustrating the decrease in the extracellular Aβ peptide deposition process in both cortical and hippocampal brain areas of representative mice chronically treated either with SAR255952 or 3D6, with respect to Ctrl-IgG1-treated mice. b Mean values of the total surface occupied by Aβ immunostaining measured over the whole cortical area from eight sections per animal. c Real-time PCR amplification of the brain inflammation marker cystatin F expression in the hippocampus. Statistical analysis of both histological and biochemical measurements denotes the significant effect of SAR255952 at 3 and 10 mg/kg injected doses in the cortex. The 3D6 effect is significant at 10 mg/kg. *p < 0.05, **p < 0.01, ***p < 0.001, versus Ctrl-IgG1-treated controls. Horizontal black lines and error bars denote mean ± SEM data

Back to article page